NICE
NICE Chief Sir Andrew Dillon to step down in 2020
August 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK pharma, UK< pharma
It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible …
NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation
August 21, 2019Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma
AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
NICE reject Clovis Oncology’s ovarian cancer drug Rubraca
August 6, 2019Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma
Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib). On 6 August, NICE issued …
Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease
August 1, 2019Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma
NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …
Top Ten most popular articles on Pharmafile.com this week
July 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten
At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers
July 26, 2019Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma
NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …
NICE to review its decision making processes
July 22, 2019Sales and Marketing Cost, NHS, NICE, UK, britain, pharma
Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, …
NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer
July 17, 2019Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma
Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …
Top Ten most popular articles on Pharmafile.com this week!
July 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HPV, NHS, NICE, Novartis, Pfizer, Trump, pharma, vaccines
This week’s most popular story covered news of Trump’s claims that he will introduce an executive order to ensure the …
NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer
July 5, 2019Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma
NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …
Alimera Sciences secures NICE recommendation for uveitis eye implant
June 21, 2019Medical Communications, Sales and Marketing Alimera Sciences, NICE, UK, pharma, uveitis
Britain’s cost effectiveness body NICE has recommended the use of the fluocinolone acetonide implant, a new treatment option for patients …
NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population
June 19, 2019Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma
Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …
RCP calls on NICE to update guidelines on coming off antidepressants
May 31, 2019Medical Communications Guidelines, NICE, RCP, antidepressants, health, pharma
Guidance for patients on coming off antidepressants needs to be updated, according to the Royal College of Psychiatrists (RCP). Current …
NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant
May 31, 2019Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma
MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …
Latest content
FibroFind appoints Lee Borthwick as CEO
